Takei Y - Search Results

1

Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion.

Sato W, Takei Y, Yuzawa Y, Matsuo S, Kadomatsu K, Muramatsu T. Sato W, et al. Among authors: takei y. Kidney Int. 2005 Apr;67(4):1330-9. doi: 10.1111/j.1523-1755.2005.00210.x. Kidney Int. 2005. PMID: 15780085 Free article.

2

5'-,3'-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy.

Takei Y, Kadomatsu K, Itoh H, Sato W, Nakazawa K, Kubota S, Muramatsu T. Takei Y, et al. J Biol Chem. 2002 Jun 28;277(26):23800-6. doi: 10.1074/jbc.M112100200. Epub 2002 Apr 16. J Biol Chem. 2002. PMID: 11959856 Free article.

3

Lack of the growth factor midkine enhances survival against cisplatin-induced renal damage.

Kawai H, Sato W, Yuzawa Y, Kosugi T, Matsuo S, Takei Y, Kadomatsu K, Muramatsu T. Kawai H, et al. Among authors: takei y. Am J Pathol. 2004 Nov;165(5):1603-12. doi: 10.1016/S0002-9440(10)63417-7. Am J Pathol. 2004. PMID: 15509530 Free PMC article.

4

Morpholino antisense oligomer targeting human midkine: its application for cancer therapy.

Takei Y, Kadomatsu K, Yuasa K, Sato W, Muramatsu T. Takei Y, et al. Int J Cancer. 2005 Apr 10;114(3):490-7. doi: 10.1002/ijc.20781. Int J Cancer. 2005. PMID: 15578698

5

Antisense oligodeoxyribonucleotide as to the growth factor midkine suppresses neointima formation induced by balloon injury.

Hayashi K, Banno H, Kadomatsu K, Takei Y, Komori K, Muramatsu T. Hayashi K, et al. Among authors: takei y. Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2203-9. doi: 10.1152/ajpheart.00555.2004. Epub 2005 Jan 6. Am J Physiol Heart Circ Physiol. 2005. PMID: 15637123 Free article.

6

Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts.

Takei Y, Kadomatsu K, Goto T, Muramatsu T. Takei Y, et al. Cancer. 2006 Aug 15;107(4):864-73. doi: 10.1002/cncr.22068. Cancer. 2006. PMID: 16832814 Free article.

7

Lymphatic vessels develop during tubulointerstitial fibrosis.

Sakamoto I, Ito Y, Mizuno M, Suzuki Y, Sawai A, Tanaka A, Maruyama S, Takei Y, Yuzawa Y, Matsuo S. Sakamoto I, et al. Among authors: takei y. Kidney Int. 2009 Apr;75(8):828-38. doi: 10.1038/ki.2008.661. Epub 2009 Jan 14. Kidney Int. 2009. PMID: 19145238 Free article.

8

Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells.

Takei Y, Kadomatsu K, Matsuo S, Itoh H, Nakazawa K, Kubota S, Muramatsu T. Takei Y, et al. Cancer Res. 2001 Dec 1;61(23):8486-91. Cancer Res. 2001. PMID: 11731432

9

Midkine expression is associated with postnatal development of the lungs.

Matsuura O, Kadomatsu K, Takei Y, Uchimura K, Mimura S, Watanabe K, Muramatsu T. Matsuura O, et al. Among authors: takei y. Cell Struct Funct. 2002 Apr;27(2):109-15. doi: 10.1247/csf.27.109. Cell Struct Funct. 2002. PMID: 12207052 Free article.

10

A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics.

Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. Takei Y, et al. Cancer Res. 2004 May 15;64(10):3365-70. doi: 10.1158/0008-5472.CAN-03-2682. Cancer Res. 2004. PMID: 15150085

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,595 results

Search Page

Filters